Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Sphingosine-1-phosphate receptor modulators
6 evidence topics · 6 sources
ACG 2025 guideline: recommendations for induction and maintenance
Mechanism and pivotal trial results: ACG 2025 evidence summary
ECCO 2026 guideline: recommendations and etrasimod safety
Ozanimod: indication, mechanism, dosing, and monitoring
Etrasimod: indication, mechanism, and dosing
Network meta-analyses: rankings of sphingosine-1-phosphate receptor modulators
“After excluding JAK inhibitors as potential first-line treatment (in accordance with FDA), low-certainty evidence supports clinically important benefit with infliximab, ozanimod, risankizumab and guselkumab over adalimumab and mirikizumab for achieving remission with induction therapy in biologic-naïve patients with moderate-severe UC, with risankizumab and ozanimod being ranked the highest for induction of clinical remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote